Business Combination - Additional Information (Detail)		3 Months Ended		5 Months Ended	9 Months Ended		12 Months Ended
	May 04, 2017 USD ($) $ / shares shares	Sep. 30, 2017 USD ($) $ / shares	Sep. 30, 2016 USD ($)	Sep. 30, 2017 USD ($) $ / shares	Sep. 30, 2017 USD ($) $ / shares	Sep. 30, 2016 USD ($)	Dec. 31, 2016 $ / shares
Business Acquisition [Line Items]
Share exchange ratio					1-for-1 basis
Debt converted in to equity	316,734
Conversion of stock | shares	6,883,498
Common stock, par value | $ / shares	$ 0.0001	$ 0.0001		$ 0.0001	$ 0.0001		$ 0.0001
Transaction costs	$ 1,673,695
Discount rate	23.00%
Revenue		$ 4,591,940	$ 901,039		$ 7,929,484	$ 2,151,915
Net loss		(29,905,237)	$ (4,795,059)		(37,594,401)	$ (8,024,985)
Restricted Stock Units (RSUs) [Member]
Business Acquisition [Line Items]
Conversion of stock | shares	39,758
Series B Preferred Stock [Member]
Business Acquisition [Line Items]
Conversion of preferred stock	$ 599,285
Common Stock Class A [Member]
Business Acquisition [Line Items]
Common stock issued | shares	6,883,498
United States [Member]
Business Acquisition [Line Items]
Operating loss carryforwards		$ 1,000,000		$ 1,000,000	$ 1,000,000
Operating loss carryforwards, expiration date					Jan. 01, 2023
Common Stock Warrants [Member]
Business Acquisition [Line Items]
Conversion of stock | shares	660,715
PharmAthene [Member]
Business Acquisition [Line Items]
Reverse stock split of common stock	0.749106
Equity interests acquired	58.20%
Total fair value of consideration	$ 44,742,737
Outstanding unvested options | shares	7,569
Stock options estimated fair value	$ 15,173
Increase tax refund receivable due to adjustments to the allocation of the purchase consideration				44,700
Reduce deferred tax liability due to adjustments to the allocation of the purchase consideration				4,535
Increase in goodwill due to adjustments to the allocation of the purchase consideration				49,235
Change in tax rate					35.00%		34.00%
Revenue				1,052,007
Net loss				$ 343,509